Is this a Prime Time To acquire NeuBase Therapeutics Inc. (NBSE) stock

The price of NeuBase Therapeutics Inc. (NASDAQ: NBSE) closed at $0.27 in the last session, down -5.31% from day before closing price of $0.29. In other words, the price has decreased by -$0.0152 from its previous closing price. On the day, 651517 shares were traded. NBSE stock price reached its highest trading level at $0.2868 during the session, while it also had its lowest trading level at $0.2590.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



We take a closer look at NBSE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 12, 2021, Reiterated its Buy rating but revised its target price to $18 from $15 previously.

On June 16, 2020, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $16.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 30 when Mann William Roland bought 6,200 shares for $1.92 per share. The transaction valued at 11,904 led to the insider holds 11,200 shares of the business.

Branning Todd P. bought 10,000 shares of NBSE for $18,100 on Mar 18. The Chief Financial Officer now owns 30,000 shares after completing the transaction at $1.81 per share. On Mar 17, another insider, Branning Todd P., who serves as the Chief Financial Officer of the company, bought 10,000 shares for $1.74 each. As a result, the insider paid 17,400 and bolstered with 20,000 shares of the company.

Stock Price History:

Over the past 52 weeks, NBSE has reached a high of $2.08, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is 0.2272, while the 200-Day Moving Average is calculated to be 0.6582.

Shares Statistics:

According to the various share statistics, NBSE traded on average about 258.99K shares per day over the past 3-months and 385.15k shares per day over the past 10 days. A total of 32.28M shares are outstanding, with a floating share count of 30.02M. Insiders hold about 2.50% of the company’s shares, while institutions hold 37.20% stake in the company. Shares short for NBSE as of Oct 13, 2022 were 352.99k with a Short Ratio of 0.40M, compared to 331.69k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.09% and a Short% of Float of 1.15%.

Earnings Estimates

The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.3, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.2 and low estimates of -$0.3.

Analysts are recommending an EPS of between -$0.96 and -$1.1 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.75, with 4 analysts recommending between -$0.17 and -$1.15.